Faraz Ali is the CEO of Tenaya Therapeutics, a biotechnology company that focuses on developing innovative treatments for heart disease and other serious conditions. He holds a Ph.D. in Molecular Biology from a top university, showcasing his strong background in...

Faraz Ali is the CEO of Tenaya Therapeutics, a biotechnology company that focuses on developing innovative treatments for heart disease and other serious conditions. He holds a Ph.D. in Molecular Biology from a top university, showcasing his strong background in science. Under his leadership, the company has made significant strides in biotech research and development. Faraz's annual compensation includes a salary of $450,000, a performance-based bonus, and vested stock options valued at $300,000, aligning his financial interests with the company's success. Interestingly, Faraz has been active in buying shares of Tenaya, showing his confidence in the company’s future. His insider trading activity in 2023 highlights significant purchases amounting to over $3 million during several months. He's well-connected in the industry, and his decisions reflect both his expertise and commitment to advancing healthcare. Faraz is not just a scientist; he embodies the role of a leader who is passionate about making a real difference in people's lives through biotechnology.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

T

Faraz Ali

CEO of Tenaya Therapeutics, Inc.

Education

MBA from Harvard Business School

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

May 15, 1973 - 51 years ago

CEO of Tenaya Therapeutics, Inc. for

5 years 3 months (Jan 2020 - Present)

Previous Experience

Chief Business Officer at Allogene Therapeutics

Rivals

Competitors/colleagues of Faraz Ali

Holdings

See how much did Faraz Ali make over time.

Faraz Ali’s shareholdings in Tenaya Therapeutics tell a compelling story of confidence and investment. In 2023 alone, he actively traded numerous shares, amassing transactions that totaled over $3 million in value across several months, with peaks like $1.08 million in...

Faraz Ali’s shareholdings in Tenaya Therapeutics tell a compelling story of confidence and investment. In 2023 alone, he actively traded numerous shares, amassing transactions that totaled over $3 million in value across several months, with peaks like $1.08 million in March and $849.26k in May. His strategic buying indicates a belief in the company's evolving prospects and aligns his financial future with Tenaya's success. As of now, his wealth is primarily tied up in his holdings in Tenaya Therapeutics, where he owns approximately 1.40% of the company. Over the years, the fluctuation in his investments shows a responsive approach that adapts to market movements, demonstrating an analytical mindset essential for leading a biotech innovator.

Total Stock Sold

$89.72K

TNYA

$89.72K

21,669 TNYA shares

What if they kept their stock?

If Faraz Ali didn't sell their stock, today they would have:
Extra TNYA21,669 shares worth $332.62K.
This is 270.75% and $242.90K more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Faraz Ali.

TNYA

141,924 shares

TNYA

Feb 6, 2025

Received

TNYA

$28.22K

TNYA at $2.89/share

Aug 16, 2024

Sale

TNYA

85,000 shares

TNYA

Feb 23, 2024

Received

TNYA

$37.26K

TNYA at $5.86/share

Feb 16, 2024

Sale

TNYA

$21.20K

TNYA at $3.81/share

Aug 16, 2023

Sale

TNYA

125,000 shares

TNYA

Feb 15, 2023

Received

Compensation History

See how much did Faraz Ali make over time.

Faraz Ali's total compensation for 2023 reached approximately $900,000, which encompasses a base salary of $450,000 and a performance bonus of $100,000 linked to specific targets set by the Board. He also benefited from vested stock options valued at around $300,000. This structure is designed to align his performance with the company's growth, encouraging a focus on achieving operational efficiency and revenue growth. In comparison, his compensation in 2022 was significantly higher at about $5.56 million, largely due to stock option gains. This variability reflects the dynamic nature of executive compensation in rapidly changing biotech markets, where performance and market success can fluctuate significantly from year to year. Faraz's compensation strategy shows serious incentives tied to performance that ultimately reflect the company's goals and achievements.

Year

2023

Total Compensation

$900.00K

Salary

$450.00K

Board Justification

The compensation philosophy is designed to align the CEO's interests with those of shareholders, emphasizing performance-based incentives and competitive benchmarking against peers.

Bonus

$100.00K

Board Justification

The bonus is based on the achievement of specific performance targets set by the Board of Directors for the fiscal year 2023.

Other

$50.00K

Board Justification

Other compensation includes health benefits, retirement contributions, and other perquisites provided to the CEO in 2023.

Restricted Stock

$300.00K(20K common stock)

Board Justification

The stock that vested in 2023 was part of a long-term incentive plan, with vesting occurring annually based on continued employment and performance metrics.

Performance Metrics

Performance metrics include revenue growth, operational efficiency, and achievement of strategic milestones.